Seaport Therapeutics SPTX

NASDAQ SPTX

$20.67 +0.06 (+0.29%)

As of: Oct 26, 2026 · 2:16 PM EDT

Seaport Therapeutics (SPTX) stock price is $20.67, up 0.29% on the day, as of Oct 26, 2026. It is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats

Add ratio to table…

About

Seaport Therapeutics, Inc. is a clinical stage therapeutics company focused on inventing and developing new medicines for patients with depression anxiety and other debilitating neuropsychiatric disorders. The company’s core activity is to take clinically validated molecules that suffer from high first pass metabolism low bioavailability or side effects and to apply its proprietary Glyph platform to create lymphatic targeting prodrugs. Glyph is designed to bypass the liver on first pass allowing the drug to enter systemic circulation via the intestinal lymphatic system. This approach aims to increase oral exposure reduce dose related toxicity and generate new composition of matter intellectual property. Seaport’s lead product candidate is GlyphAllo which is a glyphed oral prodrug of allopregnanolone intended for the treatment of major depressive disorder. Another lead candidate is GlyphAgo a glyphed oral prodrug of agomelatine targeted at generalized anxiety disorder. The company also has earlier stage programs such as Glyph2BLSD a glyphed prodrug of 2 bromo LSD for treatment resistant depression post traumatic stress disorder and headache disorders. Seaport aims to advance these candidates through clinical trials to eventually deliver therapies that address significant unmet need in neuropsychiatry.

Seaport Therapeutics, Inc. has not yet generated commercial product revenue because its candidates remain in preclinical or clinical development stages. The company funds its operations primarily through equity financing from venture capital firms and strategic investors. Since its inception Seaport has raised approximately three hundred twenty five million dollars in net proceeds to support research discovery preclinical studies and clinical trials. In addition the company may seek future revenue from licensing collaborations milestone payments or royalties should its products advance to commercialization. The current financial strategy emphasizes preserving cash to advance the GlyphAllo and GlyphAgo programs through pivotal trials while maintaining flexibility to explore additional pipeline opportunities.

Seaport Therapeutics, Inc. operates in a highly competitive biopharmaceutical landscape where large multinational pharmaceutical companies and specialized biotechs pursue treatments for depression anxiety and related neuropsychiatric conditions. Direct competitors for its lead candidate GlyphAllo include Janssen Pharmaceuticals with Spravato AbbVie with Vraylar Takeda and Lundbeck with Trintellix Axsome with Auvelity and Otsuka with Rexulti and Abilify. For GlyphAgo the competitive landscape includes Viatris with Lyrica and buspirone as well as generic selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Beyond these established products Seaport also faces competition from other clinical stage assets such as Xenon Pharmaceuticals azetukalner Alto Neuroscience ALTO 300 and ALTO 203 Cybin CYB003 and various investigational psychedelic or non hallucinogenic compounds. The company’s competitive advantages stem from its proprietary Glyph platform which enables oral delivery of drugs that are otherwise limited by high first pass metabolism potentially improving patient convenience and reducing the need for invasive administration. Additionally the platform creates new chemical entities that can be patented providing a barrier to entry. The management team’s extensive track record in bringing neuropsychiatric medicines to market including involvement with products such as Zyprexa Cymbalta Latuda and the recently approved Cobenfy offers expertise in clinical trial design patient recruitment and regulatory navigation. These factors together position Seaport to differentiate its candidates in a crowded market.

Seaport Therapeutics, Inc. intends to serve patients suffering from major depressive disorder generalized anxiety disorder and other neuropsychiatric conditions once its product candidates receive regulatory approval. The target patient population includes adults experiencing persistent low mood loss of interest anxiety symptoms sleep disturbances and related impairments that affect daily functioning and quality of life. In addition to patients the company expects to engage with healthcare providers such as psychiatrists primary care physicians and advanced practice clinicians who will prescribe the therapies. Hospitals clinics and managed care organizations are also anticipated to play a role in coverage reimbursement and distribution of the medicines. By focusing on disorders with high prevalence and limited effective treatment options Seaport aims to address a substantial unmet medical need while building a broad base of potential customers.

Investment Thesis

▲ Bull case

Seaport Therapeutics successfully raised approximately $255 million in its upsized IPO, significantly exceeding its initial target of $212.4 million, which reflects strong investor confidence in the company’s neuropsychiatric pipeline despite the crowded biotech IPO landscape. This capital infusion provides a substantial runway to advance GlyphAllo, its lead oral candidate for major depressive disorder, through later-stage clinical trials without immediate dilution concerns, allowing management to focus on execution rather than financing. The oversubscription suggests that investors are particularly bullish on the oral delivery mechanism for neuropsychiatric indications, which could offer advantages over existing injectable or intravenous therapies in terms of patient adherence and market accessibility. With GlyphAllo targeting a large and underserved patient population suffering from treatment-resistant depression, the company is positioned to capture meaningful share if clinical efficacy and safety profiles meet expectations, especially given the high unmet need and premium pricing potential in this therapeutic area.
The timing of Seaport’s IPO coincides with a broader reopening of the U.S. IPO window driven by improving risk appetite and stronger institutional sentiment, creating a favorable environment for biotech valuations that may not be fully reflected in current public market comparables. Unlike many peers that delayed offerings due to volatility, Seaport’s ability to price and upsize its deal indicates that investors are differentiating its science and de-risked clinical stage from more speculative early-stage entrants, suggesting the market may be underestimating the quality of its asset base. Furthermore, the involvement of top-tier underwriters including Goldman Sachs, J.P. Morgan, and Leerink Partners signals institutional endorsement that could support post-IPO liquidity and analyst coverage, reducing the typical volatility seen in newly listed biotechs. This structural tailwind, combined with a clearsighted focus on oral neuropsychiatric therapeutics, may allow Seaport to outperform peers as it progresses toward key clinical milestones.

Seaport Therapeutics successfully raised approximately $255 million in its upsized IPO, significantly exceeding its initial target of $212.4 million, which reflects strong investor confidence in the company’s neuropsychiatric pipeline despite the crowded biotech IPO landscape. This capital infusion provides a substantial runway to advance GlyphAllo, its lead oral candidate for major depressive disorder, through later-stage clinical trials without immediate dilution concerns, allowing management to focus on execution rather than financing. The oversubscription suggests that investors are particularly bullish on the oral delivery mechanism for neuropsychiatric indications, which could offer advantages over existing injectable or intravenous therapies in terms of patient adherence and market accessibility. With GlyphAllo targeting a large and underserved patient population suffering from treatment-resistant depression, the company is positioned to capture meaningful share if clinical efficacy and safety profiles meet expectations, especially given the high unmet need and premium pricing potential in this therapeutic area.
The timing of Seaport’s IPO coincides with a broader reopening of the U.S. IPO window driven by improving risk appetite and stronger institutional sentiment, creating a favorable environment for biotech valuations that may not be fully reflected in current public market comparables. Unlike many peers that delayed offerings due to volatility, Seaport’s ability to price and upsize its deal indicates that investors are differentiating its science and de-risked clinical stage from more speculative early-stage entrants, suggesting the market may be underestimating the quality of its asset base. Furthermore, the involvement of top-tier underwriters including Goldman Sachs, J.P. Morgan, and Leerink Partners signals institutional endorsement that could support post-IPO liquidity and analyst coverage, reducing the typical volatility seen in newly listed biotechs. This structural tailwind, combined with a clearsighted focus on oral neuropsychiatric therapeutics, may allow Seaport to outperform peers as it progresses toward key clinical milestones.

▼ Bear case

Despite the successful IPO, Seaport Therapeutics remains a clinical-stage company with no approved products and significant execution risk, as its lead candidate GlyphAllo is still in development for major depressive disorder with no public disclosure of clinical trial phases or data in the provided news, raising concerns about the maturity of its pipeline and proximity to revenue generation. The company is entering a highly competitive neuropsychiatric market dominated by established players with entrenched therapies and robust intellectual property, where differentiation through oral delivery alone may not suffice without compelling efficacy or safety advantages, especially given the high failure rates in CNS drug development. Without visibility into trial timelines, endpoints, or interim results, investors may be overpaying for future potential that is not yet substantiated by data, making the valuation sensitive to any clinical setbacks or delays that could erode the post-IPO premium.
The broader IPO momentum described in the news may be transient, driven by temporary risk appetite rather than fundamental improvements in biotech financing sustainability, meaning Seaport could face renewed funding challenges if market sentiment shifts before it achieves key milestones, particularly if its clinical programs encounter delays or unfavorable outcomes. Additionally, the simultaneous IPOs of Hemab Therapeutics and other companies in overlapping or adjacent sectors suggest increasing competition for investor capital within the biotech space, which could compress valuations and limit follow-on funding options for Seaport if it needs to return to the market sooner than anticipated. The lack of discussion around partnerships, licensing deals, or proprietary platform advantages in the news further implies that the company may be relying solely on internal development, increasing both financial and technical risk as it scales operations without external validation or de-risking through collaboration.

Despite the successful IPO, Seaport Therapeutics remains a clinical-stage company with no approved products and significant execution risk, as its lead candidate GlyphAllo is still in development for major depressive disorder with no public disclosure of clinical trial phases or data in the provided news, raising concerns about the maturity of its pipeline and proximity to revenue generation. The company is entering a highly competitive neuropsychiatric market dominated by established players with entrenched therapies and robust intellectual property, where differentiation through oral delivery alone may not suffice without compelling efficacy or safety advantages, especially given the high failure rates in CNS drug development. Without visibility into trial timelines, endpoints, or interim results, investors may be overpaying for future potential that is not yet substantiated by data, making the valuation sensitive to any clinical setbacks or delays that could erode the post-IPO premium.
The broader IPO momentum described in the news may be transient, driven by temporary risk appetite rather than fundamental improvements in biotech financing sustainability, meaning Seaport could face renewed funding challenges if market sentiment shifts before it achieves key milestones, particularly if its clinical programs encounter delays or unfavorable outcomes. Additionally, the simultaneous IPOs of Hemab Therapeutics and other companies in overlapping or adjacent sectors suggest increasing competition for investor capital within the biotech space, which could compress valuations and limit follow-on funding options for Seaport if it needs to return to the market sooner than anticipated. The lack of discussion around partnerships, licensing deals, or proprietary platform advantages in the news further implies that the company may be relying solely on internal development, increasing both financial and technical risk as it scales operations without external validation or de-risking through collaboration.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,143.90 Bn	42.82	14.36	54.91 Bn
2	JNJ	Johnson & Johnson	640.38 Bn	39.79	6.45	44.65 Bn
3	ABBV	AbbVie Inc.	506.80 Bn	80.32	7.87	70.82 Bn
4	MRK	Merck & Co., Inc.	348.18 Bn	109.73	5.23	53.91 Bn
5	NVS	Novartis Ag	298.06 Bn	18.89	5.44	9.59 Bn
6	AZN	Astrazeneca Plc	265.42 Bn	25.41	4.52	32.35 Bn
7	AMGN	Amgen Inc	238.64 Bn	27.30	6.26	57.30 Bn
8	GILD	Gilead Sciences, Inc.	196.93 Bn	-60.78	6.47	26.25 Bn

Seaport Therapeutics SPTX

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password